Cytosorbents (CTSO) Regains Nasdaq Compliance

CytoSorbents Corporation (NASDAQ: CTSO) announces that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share.

On July 26, 2024, CytoSorbents received notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) that it has regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of CytoSorbents’ common stock being $1.00 per share or greater for 10 consecutive trading sessions ending July 25, 2024. Accordingly, Nasdaq has determined that this matter is now closed.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to confirm that CytoSorbents is now back in full compliance with Nasdaq’s listing requirements, strengthening our market position as we approach our expected regulatory submissions for DrugSorb^®-ATR marketing approval to U.S. FDA and Health Canada in the next several months. With recent operational progress on the clinical, regulatory, commercial, manufacturing, and financing fronts, coupled with continued aggressive cost cutting, we have been systematically putting into place the foundation of what we believe will be an exciting new phase of our business.”

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Vishay launches thick film power resistor series with 650 W output